The Danish pharmaceutical company Novo Nordisk is set to acquire Inversago Pharma, a privately held obesity drug manufacturer, for a potential sum of $1.08 billion. The move aims to expand Novo Nordisk’s weight loss product lineup, capitalising on the success of its Wegovy and Ozempic injections. Inversago Pharma takes a unique approach to tackling obesity and diabetes, using drugs that target a brain protein called cannabinoid receptor type 1 to influence metabolism and appetite regulation. In contrast, Novo Nordisk’s drugs mimic gut-produced hormones to suppress appetite. The acquisition is expected to enhance Novo Nordisk’s clinical development pipeline for obesity and related conditions. Inversago’s leading oral therapy demonstrated promise in clinical trials, showing an average weight loss of 7.7 pounds in 28 days. The deal is anticipated to close by year’s end.
Global News and Digital Insights
for the Healthcare Industry
Menu
